EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2000EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER GARY STEINBERG, ROBERT BAHNSON, STANLEY BROSMAN, RICHARD MIDDLETON, ZEV WAJSMAN, MICHAEL WEHLE, and THE VALRUBICIN STUDY GROUP‡ GARY STEINBERGGARY STEINBERG More articles by this author , ROBERT BAHNSONROBERT BAHNSON More articles by this author , STANLEY BROSMANSTANLEY BROSMAN More articles by this author , RICHARD MIDDLETONRICHARD MIDDLETON More articles by this author , ZEV WAJSMANZEV WAJSMAN More articles by this author , MICHAEL WEHLEMICHAEL WEHLE More articles by this author , and THE VALRUBICIN STUDY GROUP‡ More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67799-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assess the efficacy and safety of intravesical valrubicin for the treatment of carcinoma in situ in patients with failure or recurrence after bacillus Calmette-Guerin (BCG) and who otherwise would have undergone cystectomy. Total anthracycline recovery in urine samples obtained within 24 hours of valrubicin administration was assessed in a subset of patients. Materials and Methods: A total of 90 patients with recurrent carcinoma in situ after failed multiple prior courses of intravesical therapy, including at least 1 course of BCG, participated in this open label, noncomparative study. Each patient received 6 weekly instillations of 800 mg. intravesical valrubicin. Disease evaluations were made at baseline and 3-month intervals following treatment. Evaluations included cystoscopy with biopsy and urine cytology. Toxicity was noted throughout treatment and followup. No evidence of disease recurrence for 6 months or greater was considered a complete response. Results: Of 90 patients 19 (21%) had a complete response, including 7 who remained disease-free at the last evaluation, with a median followup of 30 months. Additionally, 14 patients who did not meet the strict protocol definition of complete response had superficial Ta disease only. Median time to failure and/or last followup for complete responders was greater than 18 months. Recurrence has been noted in 79 patients to date, including only 2 with clinically advanced disease (stage T2). Of these 79 patients 44 (56%, 4 responders and 40 nonresponders) underwent radical cystectomy. Of the 41 patients with known pathological stage 6 (15%) had stage pT3 or greater at cystectomy. Four patients died of bladder cancer during the median followup of 30 months, none of whom was a complete responder or underwent cystectomy following valrubicin. The main side effects of valrubicin therapy were reversible local bladder symptoms. Conclusions: Valrubicin was effective and well tolerated in patients with carcinoma in situ of the bladder refractory to BCG therapy. Delaying cystectomy while attempting salvage therapy with valrubicin does not pose an undue risk to most patients. References 1 : Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology1997; 49: 687. Google Scholar 2 : Carcinoma in situ of the bladder. J Urol1995; 153: 564. Link, Google Scholar 3 : Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol1990; 144: 652. Link, Google Scholar 4 : Carcinoma in situ. Urol Clin North Am1992; 19: 499. Google Scholar 5 : The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol1990; 143: 710. Link, Google Scholar 6 : Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group study. J Urol1997; 157: 213. abstract 831. Google Scholar 7 : When intravesical measures fail: indications for cystectomy in superficial disease. Urol Clin North Am1992; 19: 601. Google Scholar 8 : Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol1987; 137: 220. Link, Google Scholar 9 : A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol1996; 156: 372. Link, Google Scholar 10 : Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology1996; 48: 21. Google Scholar 11 : Superficial bladder cancer: the role of interferon-alpha. J Urol1998; 159: 1793. Link, Google Scholar 12 : Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure. J Urol1996; 155: 494A. abstract 735. Google Scholar 13 : Management of bladder cancer in the elderly. In: . : Lippincott-Raven1997: 307. chapt. 29. Google Scholar 14 : Management of prostate and bladder cancer in the elderly. Urol Clin North Am1996; 23: 87. Google Scholar 15 : Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer1996; 78: 1089. Google Scholar 16 : Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology1997; 49: 471. Google Scholar 17 : Results of a contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol1991; 145: 45. Abstract, Google Scholar 18 : Radical cystectomy for stages Ta, TIS and T1 transitional cell carcinoma of the bladder. J Urol1994; 151: 31. Link, Google Scholar From the University of Chicago Hospitals, Chicago, Illinois, Ohio State University, Columbus, Ohio, Santa Monica Urologic Group, Santa Monica, California, University of Utah Medical Center, Salt Lake City, Utah, and University of Florida Medical College, Gainesville and Department of Urology, Mayo Clinic, Jacksonville, Florida© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByMcElree I, Packiam V, Steinberg R, Mott S, Gellhaus P, Nepple K and O'Donnell M (2022) Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder CancerJournal of Urology, VOL. 208, NO. 5, (969-977), Online publication date: 1-Nov-2022.DeCastro G, Sui W, Pak J, Lee S, Holder D, Kates M, Virk R, Drake C, Anderson C, James B, Abate-Shen C and McKiernan J (2020) A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the BladderJournal of Urology, VOL. 204, NO. 2, (247-253), Online publication date: 1-Aug-2020.Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J and Kamat A (2014) Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-GuérinJournal of Urology, VOL. 193, NO. 4, (1135-1143), Online publication date: 1-Apr-2015.McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M, Badalato G, Roychoudhury A, Decastro G and Benson M (2014) Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment FailureJournal of Urology, VOL. 192, NO. 6, (1633-1638), Online publication date: 1-Dec-2014.Lotan Y (2013) The Challenge of Bacillus Calmette-Guérin Failure in Nonmuscle Invasive Bladder Cancer—What is the Next Step in Management?Journal of Urology, VOL. 190, NO. 3, (832-833), Online publication date: 1-Sep-2013.Dinney C, Fisher M, Navai N, O'Donnell M, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman H, Kamat A, Gonzales M, Kincaid M, Ainslie N, Maneval D, Wszolek M and Benedict W (2013) Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 190, NO. 3, (850-856), Online publication date: 1-Sep-2013.Burke J, Lamm D, Meng M, Nemunaitis J, Stephenson J, Arseneau J, Aimi J, Lerner S, Yeung A, Kazarian T, Maslyar D and McKiernan J (2012) A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 188, NO. 6, (2391-2397), Online publication date: 1-Dec-2012.Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett M and MacDonald G (2012) A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-GuérinJournal of Urology, VOL. 188, NO. 5, (1712-1718), Online publication date: 1-Nov-2012.Wosnitzer M, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack D, Benson M, McKiernan J and Cordon-Cardo C (2011) Predictive Value of Microtubule Associated Proteins Tau and Stathmin in Patients With Nonmuscle Invasive Bladder Cancer Receiving Adjuvant Intravesical Taxane TherapyJournal of Urology, VOL. 186, NO. 5, (2094-2100), Online publication date: 1-Nov-2011.Morales A, Phadke K and Steinhoff G (2009) Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has FailedJournal of Urology, VOL. 181, NO. 3, (1040-1045), Online publication date: 1-Mar-2009.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.Lerner S, Tangen C, Sucharew H, Wood D and Crawford E (2018) Patterns of Recurrence and Outcomes Following Induction Bacillus Calmette-Guerin for High Risk Ta, T1 Bladder CancerJournal of Urology, VOL. 177, NO. 5, (1727-1731), Online publication date: 1-May-2007.O’DONNELL M, LILLI K and LEOPOLD C (2018) INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 172, NO. 3, (888-893), Online publication date: 1-Sep-2004.HERR H and DALBAGNI G (2018) Defining Bacillus Calmette-Guerin Refractory Superficial Bladder TumorsJournal of Urology, VOL. 169, NO. 5, (1706-1708), Online publication date: 1-May-2003.GOMELLA L, MASTRANGELO M, McCUE P, MAGUIRE H, MULHOLLAND S and LATTIME E (2018) PHASE I STUDY OF INTRAVESICAL VACCINIA VIRUS AS A VECTOR FOR GENE THERAPY OF BLADDER CANCERJournal of Urology, VOL. 166, NO. 4, (1291-1295), Online publication date: 1-Oct-2001.MORALES A, CHIN J and RAMSEY E (2018) MYCOBACTERIAL CELL WALL EXTRACT FOR TREATMENT OF CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 166, NO. 5, (1633-1638), Online publication date: 1-Nov-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.O’DONNELL M, KROHN J and DeWOLF W (2018) SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILEDJournal of Urology, VOL. 166, NO. 4, (1300-1305), Online publication date: 1-Oct-2001. Volume 163Issue 3March 2000Page: 761-767 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordscarcinoma in situbladderbladder neoplasmsinstillation, drugMetricsAuthor Information GARY STEINBERG More articles by this author ROBERT BAHNSON More articles by this author STANLEY BROSMAN More articles by this author RICHARD MIDDLETON More articles by this author ZEV WAJSMAN More articles by this author MICHAEL WEHLE More articles by this author THE VALRUBICIN STUDY GROUP‡ More articles by this author Expand All Advertisement PDF DownloadLoading ...